SEC Comment Letter 0000000000-24-006323 to Prelude Therapeutics Inc (PRLD) (CIK 0001678660) (PRLD)
Prelude Therapeutics Inc (PRLD) (CIK 0001678660)
Date: June 3, 2024 · CIK: 0001678660 · Accession: 0000000000-24-006323
AI Filing Summary & Sentiment
File numbers found in text: 333-279829
Letter
United States securities and exchange commission logo June 3, 2024 Krishna Vaddi Chief Executive Officer Prelude Therapeutics Incorporated 175 Innovation Boulevard Wilmington, DE 19805 Re:Prelude Therapeutics Incorporated Registration Statement on Form S-3 Filed May 30, 2024 File No. 333-279829 Dear Krishna Vaddi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Bryan S. Keighery
Show Raw Text
United States securities and exchange commission logo
June 3, 2024
Krishna Vaddi
Chief Executive Officer
Prelude Therapeutics Incorporated
175 Innovation Boulevard
Wilmington, DE 19805
Re:Prelude Therapeutics Incorporated
Registration Statement on Form S-3
Filed May 30, 2024
File No. 333-279829
Dear Krishna Vaddi:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Bryan S. Keighery